PubMed=19147553; DOI=10.1158/0008-5472.CAN-08-1856
Martin Michaelis, Florian Rothweiler, Denise Klassert, Andreas von Deimling, Kristoffer Weber, Boris Fehse, Bernd Kammerer, Hans-Wilhelm Doerr, Jindrich Cinatl Jr.;
Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3.
Cancer Res. 69:416-421(2009)

PubMed=22170099; DOI=10.1038/cddis.2011.129; PMCID=PMC3252738
Martin Michaelis, Florian Rothweiler, Susanne Barth, Jaroslaw Cinatl, Marijke van Rikxoort, Nadine Loschmann, Yvonne Voges, Rainer Breitling, Andreas von Deimling, Franz Rodel, Kristoffer Weber ...Show all 17 authors... , Boris Fehse, Elisabeth Mack, Thorsten Stiewe, Hans-Wilhelm Doerr, Daniel Speidel, Jindrich Cinatl Jr.; Show fewer authors
Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells.
Cell Death Dis. 2:e243.1-e243.8(2011)

PubMed=23665679; DOI=10.1038/onc.2013.129
Elizabeth I. Sokolowski, Claire B. Turina, Ken Kikuchi, David M. Langenau, Charles Keller;
Proof-of-concept rare cancers in drug development: the case for rhabdomyosarcoma.
Oncogene 33:1877-1889(2014)